Berg T, et al. - All randomized controlled trials examining individuals treated with gemcitabine (one of many treatments that could be used both as single-agent or as combination therapy for the treatment of recurrent ovarian cancer) for recurrent ovarian cancer and reporting data on overall survival, progression-free survival and toxicity were involved in this systematic review and meta-analysis. Six randomized controlled trials that assessed gemcitabine either alone or as combination therapy were involved. The results exhibited that gemcitabine is an active and safe agent in the treatment of both platinum-sensitive and resistant recurrent ovarian cancer although it might reflect the necessity of new randomized studies in massively pretreated individuals.